Read the original article in the Portland Business Journal here.
A Portland-based startup that is developing cancer vaccines was judged the best new bioscience company by the Oregon Bioscience Association.
UbiVac landed the honor, with its product and investment potential presentation beating out 15 other startups. The company was founded by immunologistBernard A. Fox and was spun off fromOregon Health & Science University (click here to see a complete list of OHSU spinoffs).
UbiVac has licensed platform technologies from three research institutions in Oregon, Providence Health & Services, Portland State University and OHSU. It is working with National Cancer Institute-trainedclinical investigators to rapidly translate and evaluate the effectiveness of immunotherapy strategies in cancer patients.
“It shows we have made an effective case about the value and the investment-worthiness of our first-in-class cancer immunotherapies,” Fox said.
UbiVac recently received a grant to develop nanotechnology-based vaccine for HPV-induced cancers, including cervical and HPV, and cancers of the upper body, such as head, neck and squamous cell carcinoma.